Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.34 |
| ▸ | OPRL1 | P41146 | 4/20 | 0.34 |
| ▸ | APEX1 | P27695 | 1/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | S100A4 | P26447 | 1/20 | 0.33 |
| ▸ | BRCA1 | P38398 | 1/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13075702 | 0.81 | RAB9A (0.39) | RAB9AAPEX1BLMMEN1POLB | |
| SCHEMBL24925508 | 0.81 | OPRL1 (0.34) | OPRM1OPRL1 | |
| SCHEMBL22833642 | 0.68 | TSHR (0.43) | RAB9AOPRM1OPRL1APEX1BLM | |
| SCHEMBL2617913 | 0.67 | MEN1 (0.33) | RAB9AAPEX1BLMMEN1POLB | |
| SCHEMBL10350605 | 0.64 | MEN1 (0.33) | RAB9AAPEX1BLMMEN1POLB | |
| SCHEMBL3713600 | 0.63 | MEN1 (0.43) | RAB9AAPEX1BLMMEN1POLB | |
| SCHEMBL3715981 | 0.63 | RAB9A (0.41) | RAB9AAPEX1BLMSIGMAR1TSHR | |
| SCHEMBL3715423 | 0.63 | PIK3CD (0.53) | RAB9AAPEX1BLMTSHR | |
| SCHEMBL11480462 | 0.62 | PIK3CD (0.32) | MAPT | |
| SCHEMBL11471242 | 0.62 | MAPT (0.34) | MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230014226-A1 | NEW COMPOUNDS AND METHODS | BENEVOLENTAI BIO LIMITED (GB) | 2023-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230014226-A1 | NEW COMPOUNDS AND METHODS | ABL2, ABL1, ALK | RAB9A 1661/4885OPRM1 1039/4885OPRL1 1506/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.